This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
by Zacks Equity Research
Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.
Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
by Zacks Equity Research
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
by Kinjel Shah
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
by Zacks Equity Research
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
by Kinjel Shah
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
by Ahan Chakraborty
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
by Sweta Killa
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
by Kinjel Shah
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Trump's EO Targets Big Pharma Stocks like Eli Lilly
by David Bartosiak
Trump's order looking to cut prescription drug prices is bearish for drug stocks at the surface, but is the worst already priced in?
PFE vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen
by Zacks Equity Research
J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
by Zacks Equity Research
Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
by Kinjel Shah
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
by Kinjel Shah
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
A Look at Pharma ETFs After Strong Q1 Earnings
by Sweta Killa
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Company News for May 7, 2025
by Zacks Equity Research
Companies in The News Are: LLY, NEM, TSLA, ABNB